Genetic analyses uncover cellular hallmarks of bladder cancer tumors that don’t respond, but interfering with one of those characteristics in a mouse model causes tumors to shrink.
Motivated by his father’s cancer diagnosis, the Francis Crick Institute cancer geneticist has been revealing the ways tumors evolve and why they are so difficult to treat.
Mice with cancer whose KRAS proteins couldn’t link together had much better survival outcomes than those whose oncogenic mutant paired with wild-type KRAS.
Mice treated with an immunostimulant had better outcomes when researchers blocked the expression of TNFR2, a compound that helps tumors evade immune attack.